Phenotypic & Targeted: Novel approaches to drug discovery

date 28th October, 2026

Phenotypic & Targeted: Novel approaches to drug discovery

o2h Discovery has enhanced its biology expertise across therapeutic areas in Cambridge, UK, and Ahmedabad, India, utilizing advanced platforms to support all stages of preclinical drug discovery, from target validation, hit identification through to lead optimisation and IND enabling. Our Integrated Drug Discovery (IDD) approach combines biology, chemistry, and ADME capabilities to accelerate the design-make-test-analyze cycles. Our experienced biologists develop customizable assays to support potency-to-efficacy translation and mechanism-of-action characterization, with seamless collaboration between our UK and India teams. Specializing in small molecule drug discovery, we bring in-depth expertise in target biology, providing valuable insights that drive progress in complex biology projects across a broad range of therapeutic areas.
ChameLogK: A Rapid, High-Throughput Assay to Assess Bioavailability of Beyond Rule of Five Compounds

date 6th September, 2025

ChameLogK: A Rapid, High-Throughput Assay to Assess Bioavailability of Beyond Rule of Five Compounds

ChameLogK is a cutting-edge method for measuring chameleonicity, a vital factor in assessing cell permeability propensity of small molecules, including ‘Beyond Rule-of-Five’ such as PROTACs, macrocycles and peptides. Chameleonicity is ability of molecules to conformationally adapt to their environment, driven by intramolecular hydrogen bonds; ChameLogK combines lipophilicity (BRlogD) and polarity (Δlog kw IAM) descriptors. Leveraging literature methods, o2h has developed a reliable, high-throughput platform to rapidly and inexpensively measure chameleonicity, accelerating optimization of Beyond Rule-ofFive therapeutic compounds
An array of Targeted Degradation approaches offered as a part of integrated drug discovery services

date 4th February, 2025

An array of Targeted Degradation approaches offered as a part of integrated drug discovery services

Explore how o2h Discovery applies a PROTAC-like approach to RNA-targeted drug discovery. Our expertise in small molecule design, assay development, and RIBOTACs enables the creation of novel RNA degraders for next-generation therapeutics.
Integrated drug discovery services from o2h: Advancing therapeutic innovation through collaborative research

date 3rd February, 2025

Integrated drug discovery services from o2h: Advancing therapeutic innovation through collaborative research

Our Integrated Drug Discovery approach combines biology, chemistry, and ADME capabilities to accelerate the design-make-test-analyze cycles across a broad range of therapeutic areas.
High-content analysis of DNA damage markers in multiplexed cell lines using the SemaCyte® microcarrier platform

date 1st January, 2025

High-content analysis of DNA damage markers in multiplexed cell lines using the SemaCyte® microcarrier platform

High-content imaging (HCI) offers a considerable depth of analysis options when considering the requirements for developing a new cellular assay.